Vincristine

Generic Name
Vincristine
Brand Names
Marqibo, Vincasar
Drug Type
Small Molecule
Chemical Formula
C46H56N4O10
CAS Number
57-22-7
Unique Ingredient Identifier
5J49Q6B70F
Background

Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristin...

Indication

Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).

Associated Conditions
Acute Lymphoblastic Leukemia (ALL), Choriocarcinoma, Chronic Lymphocytic Leukemia, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Hepatoblastomas, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Multiple Myeloma (MM), Neuroblastoma (NB), Non-Hodgkin's Lymphoma (NHL), Ovarian germ cell tumour, Pheochromocytoma, Relapsed Acute Lymphoblastic Leukemia (ALL), Retinoblastoma, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Wilms' tumor, Advanced Thymoma
Associated Therapies
-
Clinical Trials
Related News

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

First Posted Date
2021-09-02
Last Posted Date
2024-10-22
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
4
Registration Number
NCT05032183
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)

First Posted Date
2021-08-17
Last Posted Date
2024-11-20
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
146
Registration Number
NCT05008224
Locations
🇺🇸

Stanford Cancer Center ( Site 0023), Palo Alto, California, United States

🇺🇸

Northwestern Memorial Hospital ( Site 0002), Chicago, Illinois, United States

🇺🇸

Texas Oncology-Plano East ( Site 0020), Plano, Texas, United States

and more 45 locations

A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma

First Posted Date
2021-07-28
Last Posted Date
2024-12-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
46
Registration Number
NCT04980222
Locations
🇪🇸

Hospital Clinico Universitario de Salamanca;Servicio de Hematologia, Salamanca, Spain

🇺🇸

City of Hope Comprehensive Cancer Center, Duarte, California, United States

🇺🇸

Stanford Cancer Center, Palo Alto, California, United States

and more 24 locations

Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study

First Posted Date
2021-07-27
Last Posted Date
2024-12-06
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
60
Registration Number
NCT04978584
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8)

First Posted Date
2021-07-23
Last Posted Date
2022-03-29
Lead Sponsor
ADC Therapeutics S.A.
Registration Number
NCT04974996
Locations
🇺🇸

University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States

A Study of N9 Chemotherapy in Children With Neuroblastoma

First Posted Date
2021-07-01
Last Posted Date
2024-12-02
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
26
Registration Number
NCT04947501
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas

First Posted Date
2021-06-22
Last Posted Date
2024-07-09
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
8
Registration Number
NCT04933617
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

First Posted Date
2021-06-10
Last Posted Date
2022-11-07
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Target Recruit Count
289
Registration Number
NCT04922567
Locations
🇨🇳

2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)

First Posted Date
2021-06-07
Last Posted Date
2024-08-12
Lead Sponsor
Peter MacCallum Cancer Centre, Australia
Target Recruit Count
80
Registration Number
NCT04914741
Locations
🇦🇺

Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

🇦🇺

St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia

🇦🇺

Alfred Hospital, Melbourne, Victoria, Australia

and more 12 locations

Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors

First Posted Date
2021-05-18
Last Posted Date
2024-12-06
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
64
Registration Number
NCT04890093
Locations
🇺🇸

Childrens National Medical Center, Washington, District of Columbia, United States

🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy